Molecular structure of JNK Inhibitor XVI, CAS Number: 1410880-22-6
JNK Inhibitor XVI (CAS 1410880-22-6)
See product citations (5)
Alternate Names:
JNK-IN-8
Application:
JNK Inhibitor XVI is a selective and irreversible type 2 inhibitor of JNK
CAS Number:
1410880-22-6
Purity:
≥97%
Molecular Weight:
507.59
Molecular Formula:
C29H29N7O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
JNK Inhibitor XVI is a cell-permeable, selective, and irreversible type 2 inhibitor of JNK (c-Jun N-terminal kinases) (JNK1 IC50 = 4.67 nM, JNK2 IC50 = 18.7 nM, JNK3 IC50 = 980 pM). JNK Inhibitor XVI forms a covalent adduct with the conserved cysteine residue (Cys116 in JNK1). Through its inhibitory action on JNK Inhibitor XVI, JNK Inhibitor XVI sheds light on the role of JNK in multiple processes such as cell signaling pathways, cell cycle regulation, and apoptosis. JNK Inhibitor XVI binds to and inhibits the activity of JNK, a member of the MAPK family involved in controlling cell proliferation, differentiation, and survival.
JNK Inhibitor XVI (CAS 1410880-22-6) References
- A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. | Ebelt, ND., et al. 2017. Oncotarget. 8: 104894-104912. PMID: 29285221
- Activation of AMPK inhibits inflammatory response during hypoxia and reoxygenation through modulating JNK-mediated NF-κB pathway. | Chen, X., et al. 2018. Metabolism. 83: 256-270. PMID: 29526538
- Targeting JNK pathway promotes human hematopoietic stem cell expansion. | Xiao, X., et al. 2019. Cell Discov. 5: 2. PMID: 30622738
- Cadmium-induced apoptosis through reactive oxygen species-mediated mitochondrial oxidative stress and the JNK signaling pathway in TM3 cells, a model of mouse Leydig cells. | Wang, S., et al. 2019. Toxicol Appl Pharmacol. 368: 37-48. PMID: 30796935
- JNK2 Is Required for the Tumorigenic Properties of Melanoma Cells. | Du, L., et al. 2019. ACS Chem Biol. 14: 1426-1435. PMID: 31063355
- JNK-IN-8, a c-Jun N-terminal kinase inhibitor, improves functional recovery through suppressing neuroinflammation in ischemic stroke. | Zheng, J., et al. 2020. J Cell Physiol. 235: 2792-2799. PMID: 31541462
- Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. | Lipner, MB., et al. 2020. JCI Insight. 5: PMID: 32213714
- Activation of JNK signaling promotes all-trans-retinal-induced photoreceptor apoptosis in mice. | Liao, C., et al. 2020. J Biol Chem. 295: 6958-6971. PMID: 32265302
- Specific c-Jun N-Terminal Kinase Inhibitor, JNK-IN-8 Suppresses Mesenchymal Profile of PTX-Resistant MCF-7 Cells through Modulating PI3K/Akt, MAPK and Wnt Signaling Pathways. | Ozfiliz Kilbas, P., et al. 2020. Biology (Basel). 9: PMID: 33019717
- JNK‑IN‑8 treatment alleviates lipopolysaccharide‑induced acute lung injury via suppression of inflammation and oxidative stress regulated by JNK/NF‑κB signaling. | Du, J., et al. 2021. Mol Med Rep. 23: PMID: 33355369
- GO-Y078, a Curcumin Analog, Induces Both Apoptotic Pathways in Human Osteosarcoma Cells via Activation of JNK and p38 Signaling. | Lu, PW., et al. 2021. Pharmaceuticals (Basel). 14: PMID: 34073773
- Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer. | Sun, L., et al. 2021. Oncogene. 40: 5105-5115. PMID: 34193942
- Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated With an Immunosuppressive Tumor Microenvironment. | Semba, T., et al. 2022. J Natl Cancer Inst. 114: 97-108. PMID: 34250544
- Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy. | Soleimani, M., et al. 2022. Mol Cancer Ther. 21: 1547-1560. PMID: 35977156
- JNK-IN-8 treatment improves ARDS-induced cognitive impairment by inhibiting JNK/NF-κB-mediated NLRP3 inflammasome. | Shi, Y., et al. 2023. Brain Behav. 13: e2980. PMID: 36987783
Inhibitor of:
C2orf70, Ear5, Ear6, EG626456, JIP-2, JIP-3, JNK1, JNK2, JNK3, Lamin A, LOC100041241, MAP-9, MARCO, MPK-1, Ser/Thr Protein Kinase, and T2BP.Activator of:
ASB-1, C030039L03Rik, ERK 5, MEL-28, NLF1, Nup37, POM121L, Rif1, and TRAF7.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
JNK Inhibitor XVI, 10 mg | sc-364745 | 10 mg | $357.00 |